PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9105265

Interference with testing for lysergic acid diethylamide.

D Ritter·C M Cortese·L C Edwards·J L Barr·H D Chung·C Long
View original source ↗Export metadata ↓

Abstract

We found a high rate (4.2%) of positive results for lysergic acid diethylamide (LSD) by Emit in 1898 urine samples that were submitted primarily from psychiatric patients for drugs-of-abuse (DOA) testing. Specimens that tested positive for LSD by Emit subsequently tested negative for LSD with two RIAs. Furthermore, LSD was not detected in randomly selected Emit-positive urine samples by gas chromatography-mass spectrometry. Normal urine samples tested positive for LSD by Emit when they were supplemented with therapeutic medications that were prescribed for patients with positive urine LSD results by Emit. These therapeutic drugs interfered specifically with the Emit assay for LSD, since other Emit DOA tests were not affected by these medications at the tested concentrations.

Explore related subjects

Enzyme Multiplied Immunoassay TechniqueFalse Positive ReactionsGas Chromatography-Mass SpectrometryHumansLysergic Acid DiethylamideQuality ControlRadioimmunoassaySubstance Abuse DetectionJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Ritter, C M Cortese, L C Edwards, J L Barr, H D Chung, C Long. 1997. Interference with testing for lysergic acid diethylamide.. https://pubmed.ncbi.nlm.nih.gov/9105265/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Enzymatic amplification staining for single cell analysis: applied to in situ hybridization.

Single cell analysis by flow cytometry is a powerful modality for analyzing the expression of a set of molecules. Nevertheless, the most significant deficiency of this technology has been the poor sensitivity of flow cytometry compared to other techniques such as immunoblotting. In order to address this deficiency, we have developed an enzymatic amplification system for flow cytometry that enhances the specific signal by 10-100-fold. Using enzymatic amplification staining (EAS), we and others have been able to assess the expression of molecules that could not be detected otherwise. In this review, we show the capability of this new technology to detect specific RNA expression.

Enzyme Multiplied Immunoassay Technique↗
PubMed2001

Immunophenotypic analysis with enhanced sensitivity of detection by enzymatic amplification staining.

Single cell analysis by flow cytometry is a powerful diagnostic modality that has been limited by poor resolving power. Molecules expressed on the cell surface in abundance (i.e., greater than 1000 molecules per cell) can be detected readily by conventional staining technologies; however, molecules expressed in lower concentrations cannot be easily observed. Because there are many molecules that are functionally significant at lower levels of expression, the capability to detect these molecules is important. Enzymatic amplification staining is a new flow cytometric amplification technology based on the enzymatically catalyzed deposition of reporter molecules. This technology allows for the detection of molecules expressed on the cell surface at low abundance. The authors have demonstrated that EAS can be used to resolve the expression of molecules that cannot be resolved with standard amplification procedures. It has been shown that this capability is valuable in the diagnostic evaluation of patient samples; moreover, it is likely that EAS can be profitably used in the analysis of both malignant and reactive blood cells from various patients.

Enzyme Multiplied Immunoassay Technique↗